Diabetes drug and conflicts of interest

So much for confidential peer review.

Last May, a controversial paper in the New England Journal of Medicine (NEJM) reported that a popular diabetes drug—rosiglitazone, sold as Avandia—substantially hikes a user’s risk of heart attack (SN: 6/23/07, p. 397). But according to an ongoing investigation by the U.S.